Hypoactive Sexual Desire Disorder
Hypoactive sexual desire disorder (HSDD), now known as female sexual interest/arousal disorder, is a sexual dysfunction that causes a lowered sex drive in women. Many women will pass off the symptoms of HSDD as the inevitable effects of aging or changes in their body.
Wiki Number: W099
Diagnosis: Hypoactive Sexual Desire Disorder
US Patients: 10%Women
Brain Area: in men, higher serotonin than testosterone, unbalanced;in women, mood disorders, low prolactin, relationship problems
Symptoms: lack of desire for sex or lack of sexual fantasies; if neither of a couple is distressed, this is not a problem.
Causes: in men, low testosterone or high prolactin(precursor to testosterone); no known basis for lifetime lack of interest in sex
Medications: for women: bremelnotide before menopause and flibanserin after menopause.
Therapies: Understanding the culture, some cultures emphasize sexual restraint; others, sexual expression.
4 CURRENT ARTICLES
The world-wide medical research
reports chosen for each diagnosis
Clicking each title opens the
PubMed article’s summary-abstract.
- A randomized controlled trial of an Internet-based emotion regulation intervention for sexual health: study protocolby Vinicius Jobim Fischer on October 16, 2021
INTRODUCTION: Emotion regulation difficulties have been associated with mental disorders and sexual dysfunctions. Traditional face-to-face transdiagnostic emotion regulation interventions have shown positive results for emotional and personality disorders. Only recently have the effects of these interventions on sexual health started to be investigated. Internet-delivered psychological interventions have several advantages over face-to-face interventions, such as cost-effectiveness,...
- Second-derivative synchronous fluorimetry and time-programmed HPLC-fluorescence detection for simultaneous estimation of flibanserin and sitagliptin phosphate in synthetic mixtures and human plasma samplesby Miranda F Kamal on October 15, 2021
Diabetes Mellitus is directly related to female anaphrodesia. Female Viagra or Flibanserin (FLB), U.S. FDA approved in 2015, is specifically indicated for premenopausal Hypoactive Sexual Desire Disorder, HSDD, which is one of the primary consequences of Diabetes Mellitus. Simultaneous analysis of the concomitantly administered, FLB and oral antidiabetics, as Sitagliptin phosphate (STG), is a crucial demand to investigate mutual drug-drug interaction. The latter is responsible for uncontrolled...
- Understanding female sexual dysfunction, its causes and treatmentsby Angela Gregory on October 14, 2021
Female sexual dysfunction can greatly affect a woman's quality of life. Affected patients need a comprehensive assessment that includes taking a sexual history, medical evaluation and, if appropriate, a manual examination in order to diagnose, treat or identify factors relevant for each individual woman. There may be biological, psychological, emotional and relationship issues. Any biological factors such as vaginal dryness, pelvic floor dysfunction or chronic pain need to be addressed first to...
- Bremelanotide and flibanserin for low sexual desire in women: the fallacy of regulatory precedentby Barbara Mintzes on October 13, 2021
The US Food and Drug Administration (FDA) has approved two drugs for 'hypoactive sexual desire disorder' in women, flibanserin (Addyi) in 2015 and bremelanotide (Vyleesi) in 2019. In this paper we examine the outcome measures and clinical trial data upon which regulatory approval was based. In clinical trials, flibanserin led to an average of only one additional enjoyable sexual experience every two months, bremelanotide to none. Trials for both drugs feature shifts in primary outcomes and a...